Equities

Rezolute Inc

RZLT:NAQ

Rezolute Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.58
  • Today's Change-0.14 / -2.45%
  • Shares traded561.73k
  • 1 Year change+458.00%
  • Beta1.0510
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy4
Outperform6
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The 9 analysts offering 12 month price targets for Rezolute Inc have a median target of 13.00, with a high estimate of 16.00 and a low estimate of 8.00. The median estimate represents a 132.97% increase from the last price of 5.58.
High186.7%16.00
Med133.0%13.00
Low43.4%8.00

Earnings history & estimates in USD

On Nov 07, 2024, Rezolute Inc reported 1st quarter 2025 losses of -0.22 per share. This result exceeded the -0.33 consensus loss of the 6 analysts covering the company and exceeded last year's 1st quarter results by 21.43%.
The next earnings announcement is expected on Feb 11, 2025.
Average growth rate-0.44%
Rezolute Inc reported annual 2024 losses of -1.33 per share on Sep 19, 2024.
Average growth rate+15.66%
More ▼

Revenue history & estimates in USD

Rezolute, Inc. did not report revenues for the 1st quarter 2025. However, during the 1st quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Rezolute, Inc. did not report revenues for the full year 2024. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.